Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Merck's revenue for the second quarter of 2023 was $15.04 billion, up 3.8% from the ...

The market for materials manufactured in space could reach $10 billion by 2030, according to an estimate from a McKinsey analyst.

Merck's revenues have increased by 31% over the last decade, driven by sales volume, price increases, and M&A activity. The company has a strong track record of increasing dividends annually for th...

Merck (NYSE: MRK ) has consistently delivered impressive financial results, built a robust product portfolio, and demonstrated an unwavering commitment to research and development. Given this, I th...

It's a common assumption that the best ESG (environmental, social, governance) stocks to buy may be profitable for your inner wellbeing but not necessarily for your portfolio. After all, doing the ...

The drug giant pours massive amounts into R&D -- nearly a quarter of its revenue. Seven of Merck's medications boast more than $1 billion in annual sales.

Merck's crown jewel, Keytruda, is still the star of the show. There are other pieces to the company's business.

Health is undoubtedly the most important thing for all of us. It's vital to be able to continue with our day-to-day and to be able to carry out everything we want to throughout our lives.